What question did this study set out to answer?

To review the biological properties of cancer stem cells (CSCs), examine mechanisms mediating therapeutic resistance, and outline translational strategies for incorporating CSC-targeted agents into clinical oncology.

August 14, 2026Signal Transduction and Targeted TherapyOpen Access

Translational insights and clinical challenges of targeting cancer stem cells

View Full Paper

Ask AI

Bookmark

Authors

MAMehreen AhmedUniversity of Tennessee Health Science Center AAAmr Al-HaidariUniversity of Rochester Medical Center SAShruti AgarwalSir Ganga Ram Hospital

Discussion

Member takes

Implication

Narrative review explores biological barriers and therapeutic strategies for cancer stem cells across diverse malignancies, highlighting pathways to improve durable treatment responses.

Key Points

To review the biological properties of cancer stem cells (CSCs), examine mechanisms mediating therapeutic resistance, and outline translational strategies for incorporating CSC-targeted agents into clinical oncology.
Synthesized evidence on CSC developmental pathways, microenvironmental niche signals, and stress response mechanisms conferring resistance to chemotherapy, radiation, and targeted agents.
Evaluated preclinical and clinical approaches targeting CSCs, including small molecules, monoclonal antibodies, cellular immunotherapies, vaccines, and advanced organoid or single-cell profiling platforms.
Dynamic plasticity, phenotypic heterogeneity between tumor subtypes, and supportive specialized microenvironments serve as the primary obstacles to sustained CSC eradication.
Emerging preclinical tools, including spatial profiling, lineage tracing, and patient-derived organoids, provide actionable frameworks for designing rational CSC-directed combination therapies.

Cite This Study

Ahmed et al. (2026) studied this question.

synapsesocial.com/papers/6a7ec775b70b84ec8b913ce6 https://doi.org/10.1038/s41392-026-02887-y

View Full Paper

Ask AI

Bookmark

August 14, 2026Signal Transduction and Targeted TherapyOpen Access

Translational insights and clinical challenges of targeting cancer stem cells

View Full Paper

Ask AI

Bookmark

Authors

MAMehreen AhmedUniversity of Tennessee Health Science Center AAAmr Al-HaidariUniversity of Rochester Medical Center SAShruti AgarwalSir Ganga Ram Hospital

Discussion

Member takes

Implication

Narrative review explores biological barriers and therapeutic strategies for cancer stem cells across diverse malignancies, highlighting pathways to improve durable treatment responses.

Key Points

To review the biological properties of cancer stem cells (CSCs), examine mechanisms mediating therapeutic resistance, and outline translational strategies for incorporating CSC-targeted agents into clinical oncology.
Synthesized evidence on CSC developmental pathways, microenvironmental niche signals, and stress response mechanisms conferring resistance to chemotherapy, radiation, and targeted agents.
Evaluated preclinical and clinical approaches targeting CSCs, including small molecules, monoclonal antibodies, cellular immunotherapies, vaccines, and advanced organoid or single-cell profiling platforms.
Dynamic plasticity, phenotypic heterogeneity between tumor subtypes, and supportive specialized microenvironments serve as the primary obstacles to sustained CSC eradication.
Emerging preclinical tools, including spatial profiling, lineage tracing, and patient-derived organoids, provide actionable frameworks for designing rational CSC-directed combination therapies.

Cite This Study

Ahmed et al. (2026) studied this question.

synapsesocial.com/papers/6a7ec775b70b84ec8b913ce6 https://doi.org/10.1038/s41392-026-02887-y

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark